Boston Scientific agrees to buy medical device company BridgePoint Medical and its heart blockage tool for an undisclosed amount.
Boston Scientific (NYSE:BSX) said it agreed to buy BridgePoint Medical for an undisclosed amount, adding the Minneapolis-based medical device company's technology for treating blocked blood vessels in the heart to its stable of interventional cardiology tools.
BridgePoint's technology is designed to allow cardiologists to treat coronary chronic total occlusions by threading a catheter guidewire across the blockage. Its CrossBoss CTO-crossing catheter and Stingray CTO re-entry system is cleared for sale in the U.S. and Europe, according to a press release.
BridgePoint has also developed similar technology for treating blocked blood vessels in the legs, the TruePath and OffRoad devices, which is not yet cleared for use in the U.S.
Boston Scientific said the deal, expected to close during the 4th quarter, isn't likely to affect earnings this year or in 2013 and be "modestly accretive" after that.